SPTX vs NKTR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SPTX · Seaport Therapeutics$21.50 ▲ 5.44%
NKTR · Nektar Therapeutics$37.26 ▲ 3.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SPTX +8.4%
- NKTR -56.9%
Head to head
| Metric | SPTX | NKTR |
|---|---|---|
| Price | $21.50 | $37.26 |
| Change today | ▲ 5.44% | ▲ 3.07% |
| Market cap | $1.15B | $1.27B |
| Return, 3 months | -6.6% | -50.2% |
| Return, year to date | – | -11.9% |
| Return, 1 year | – | -33.4% |
| P/E (TTM) | – | – |
| P/B | 2.9 | 1.4 |
| P/E percentile vs own 5y | 86th | 19th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -9.3% |
| Net profit growth (YoY) | -315.2% | +2.3% |
| Gross margin | – | – |
| Operating margin | – | -239.3% |
| Net margin | – | -287.8% |
| Return on equity | -31.9% | -35.8% |
| Analyst target vs. price | +71.3% | +279.3% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 58 | 36 |
| 30-day volatility | 73.7% | 91.5% |
| Max drawdown, 1 year | -42.2% | -64.3% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NKTR is the largest of the group by market value.
- SPTX has been the calmest stock over the last 30 days.